View Scopus Profile

Manu Jain

Professor, Medicine, Pulmonary Division
Professor, Pediatrics

Phone+1 312 503 4242
Emailm-jain@northwestern.edu

Source: Scopus

Research activity per year

If you made any changes in Pure these will be visible here soon.

14 Active
70 Finished

14 results

Filter

Active

Prot #AP-PA02-101: A Phase 1b/2a, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of AP-PA02 Multi-Phage Therapeutic Candidate for Inhalation in Subjects with Cys
Jain, M.
Armata Pharmaceuticals, Inc.
2/2/21 → 2/2/24
Project: Research project
Zasu IPA from 1/1/2021-05/31/2021
Jain, M.
Jesse Brown VA Medical Center
2/1/21 → 6/30/21
Project: Research project
Reimbursable Costs on A master protocol to test the impact of discontinuing chronic therapies in people with cystic fibrosis on highly effective CFTR modulator therapy (SIMPLIFY)
Jain, M.
Seattle Children's
12/17/20 → 12/16/23
Project: Research project
A master protocol to test the impact of discontinuing chronic therapies in people with cystic fibrosis on highly effective CFTR modulator therapy (SIMPLIFY)
Jain, M.
Seattle Children's, Cystic Fibrosis Foundation
12/17/20 → 12/16/23
Project: Research project
Prot #VX19-CFD-003: An Observational Study to Evaluate the Real-World Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor on the Burden of Illness in Cystic Fibrosis Patients
Jain, M.
Vertex Pharmaceuticals Incorporated
11/6/20 → 11/6/23
Project: Research project
Assessing the Transcriptional Response to Triple CFTR modulator Treatment of the Nasal Epithelium
Jain, M.
Cystic Fibrosis Foundation
1/1/20 → 12/31/21
Project: Research project
Prot #MRT5005-101: A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Combined Single and Multiple Ascending Dose Study Evaluating the Safety, Tolerability, and Biological Activity of MRT5005 (CO-hCFTR mRNA/ICE LNP) Administered by Nebulization to
Jain, M.
Rho, Inc., Translate Bio, Inc.
12/7/18 → 12/7/21
Project: Research project
Prot #PTI-428-06: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect of PTI-428 in Subjects with Cystic Fibrosis
Jain, M.
MS Clinical Services, LLC, Proteostasis Therapeutics, Inc.
10/29/18 → 10/29/21
Project: Research project
Prot #PTI-808-01: A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PTI-808 in Healthy Adult Subjects and in Adults with Cystic Fibrosis
Jain, M.
Chiltern International, Inc., Proteostasis Therapeutics, Inc.
8/2/18 → 8/2/21
Project: Research project
Prot #VX17-445-105: A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
Jain, M.
Greenphire, Inc., Vertex Pharmaceuticals Incorporated
7/29/18 → 7/29/23
Project: Research project
Prot #VX17-445-103: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del Mutation (F/F)
Jain, M.
Greenphire, Inc., Vertex Pharmaceuticals Incorporated
7/10/18 → 7/10/21
Project: Research project
Prot #VX14-661-110: A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment with VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F50
Jain, M. & Prickett, M.
Quintiles, Inc., Vertex Pharmaceuticals Incorporated
10/12/15 → 10/12/21
Project: Research project
CFF Teaching and Education Grant
Jain, M.
Cystic Fibrosis Foundation
7/1/15 → 6/30/21
Project: Research project
Therapeutics Development Center
Jain, M.
Cystic Fibrosis Foundation Therapeutics, Inc.
1/1/14 → 3/31/22
Project: Research project